Searching journal content for endocrine therapy resistance (as phrase) in full text.

Displaying results 1-10 of 36
For checked items
  1. ...endocrine therapy resistance is clinically identified at the level of recurrent disease, a clear clinical need exists to identify markers for endocrine resistance at an early stage, so that patients with a predicted resistance can be treated with an alternative treatment instead. ERα and AR both hav ~~~
  2. ...endocrine therapy resistance f hormone structure/ function T180Thematic Review I Coutinho et al. Androgen receptor signaling in CRPC DOI: 10.1530/ERC-16-0422 © 2016 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. 23:12 an AR-inde ~~~
  3. ...endocrine therapy resistance ~~~
  4. ...endocrine therapy resistance f estrogen receptor f gene transcription f prostate f coactivator f corepressor T86Thematic Review D A Leach et al. Nuclear receptors in prostate cancer DOI: 10.1530/ERC-16-0319 © 2016 Society for Endocrinology Printed in Great Britain ~~~
  5. ...endocrine therapy resistance f cell signaling Open Access 610Research H H Han et al. Angiopoietin-2 drives dormant cancer reactivation DOI: 10.1530/ERC-16-0086 © 2016 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. 23:8 Zhang et  ~~~
  6. ...endocrine therapy resistance (Johnston & Dowsett 2003). In addition, residual amounts of estrogen may still be present after treatment with aromatase inhibitors, which function by reducing estrogen biosynthesis (Dowsett Figure 4 Effects of E2 (A) and TAM (B) treatment for 24, 48, and 96 h on prolife ~~~
  7. ...endocrine therapy resistance f breast cancer Correspondence should be addressed to M N Dickler Email [email protected] R338Review C G Murphy and M N Dickler Advances in treatment for HR+ breast cancer DOI: 10.1530/ERC-16-0121 © 2016 Society for Endocrinology Print ~~~
  8. ...endocrine therapy resistance f cell lineage/genetics f clonal spread Abstract Metastatic disease is responsible for the majority of prostate cancer deaths. The standard treatment for metastatic disease is surgical or chemical castration in the form of androgen deprivation therapy. Despite initial su ~~~
  9. ...endocrine therapy resistance and is a therapeutic q 2016 Society for Endocrinology DOI: 10.1530/ERC-15-0461 Printed in Great Britaintarget in breast cancer. Cancer Research 70 2085–2094. (doi:10.1158/ 0008-5472.CAN-09-3746) Tzahar E, Waterman H, Chen X, Levkowitz G ~~~
  10. ...endocrine therapy resistance and metastasis. Unlike estrogen, progesterone seems to clearly promote the expansion of BCSCs, suggesting that anti-progesterone drugs may find clinical use in targeting BCSCs. Although the underlying mechanisms remain obscure, the BCSC-promoting effects of progesterone ~~~
For checked items